PRE-I-SPY Phase I/Ib Oncology Platform Program
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Metastatic Cancer|Metastatic Breast Cancer|Metastatic|HER2-positive Metastatic Breast Cancer|HER2 Mutation-Related Tumors|HER-2 Protein Overexpression|HER2-negative Breast Cancer|Triple Negative Breast Cancer|HR Positive|Hormone Receptor-positive Breast Cancer|Estrogen Receptor Positive Tumor|Progesterone Receptor-positive Breast Cancer|Hormone Receptor Negative Breast Carcinoma|Solid Tumor|Solid Tumor, Adult|Solid Carcinoma|HER2 Low Breast Cancer|HER2 Low Breast Carcinoma|ER Positive Breast Cancer|PR-positive Breast Cancer
Interventions: DRUG: ALX148|DRUG: Fam-Trastuzumab Deruxtecan-Nxki|DRUG: Zanidatamab|DRUG: Tucatinib
Sponsor: QuantumLeap Healthcare Collaborative